Phase 2 trial results demonstrate CAN-2409 significantly extended median overall survival to 31.4 months compared to 12.5 months in control group for borderline resectable pancreatic cancer patients.

Patient-reported outcomes and real-world evidence are increasingly influencing clinical decisions in selecting BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma treatment.

Light AI's novel algorithm demonstrates 96.57% accuracy in distinguishing between viral and bacterial pharyngitis through smartphone image analysis, with a 100% negative predictive value for Strep A detection.

CARsgen Therapeutics has partnered with Zhuhai SB Xinchuang, securing RMB 80 million investment for its subsidiary UCARsgen to develop allogeneic CAR-T cell therapies in mainland China.

BasgenBio secures a 1 billion won ($684,090) deal with Novartis to implement AI-driven digital twin technology for predicting side effects in breast cancer patients.

HTD1801, a plant-derived berberine medication, demonstrated significant blood glucose control in type 2 diabetes patients, with the highest dose reducing HbA1c by 0.7% over 12 weeks.

Distinguished neurologist Professor Patrick Vermersch identifies mast and microglia cells as key catalysts in neurodegenerative diseases, highlighting their role in conditions like multiple sclerosis and Alzheimer's disease.

New data from a 2,854-patient registry study shows Blue Light Cystoscopy detected additional malignant lesions in 7% of cases that were missed by standard white light examination.

New research reveals Breast Cancer Index (BCI) can identify approximately 20% of postmenopausal women with HR-positive, node-negative breast cancer who have minimal recurrence risk, potentially allowing for shorter endocrine therapy.

A large-scale Phase 3 trial in Burkina Faso reveals that repeated high-dose ivermectin mass drug administration did not significantly reduce malaria incidence when combined with seasonal malaria chemoprevention.

HUTCHMED has completed enrollment of 87 patients in a Phase II registration trial evaluating fanregratinib for intrahepatic cholangiocarcinoma patients with FGFR2 fusion/rearrangement.

Final analysis of CALYPSO trial demonstrates significant efficacy with savolitinib-durvalumab combination, showing 53% response rate in MET-driven papillary renal cancer patients.

A groundbreaking Phase I/II clinical trial demonstrates 93% manufacturing success rate for Cultivated Autologous Limbal Epithelial Cell (CALEC) transplantation, offering new hope for limbal stem cell deficiency patients.

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) achieved significant overall survival improvement in HER2-positive breast cancer patients during Phase III clinical trial.

Recent communications from the FDA to Xbrane Biopharma and Formycon suggest a significant shift in the agency's approach to biosimilar development requirements.

The AUA 2024 meeting showcased promising advancements in male contraceptive research, including hormonal gels and nonhormonal approaches, addressing the growing need for expanded contraceptive options following the Dobbs decision.

Recent studies reveal critical risk factors for MDS progression, including male gender and specific blood count parameters, enabling better prediction of disease advancement to acute myeloid leukemia.

The International Council for Harmonisation (ICH) has published Q5A(R2) guidelines, recommending Next-Generation Sequencing as the preferred method for viral safety evaluation in biotechnology products.

Phase 3 trial results demonstrate 1.5% ruxolitinib cream's safety and efficacy in treating atopic dermatitis in children aged 2-11 years, with no significant hematologic concerns noted.

Vanderbilt Health's Specialty Pharmacy program analysis reveals pharmacist interventions saved between $129,705 and $162,133 monthly through medication management, including discontinuations, dose adjustments, and therapeutic switches.